Acura Pharmaceuticals Inc. (ACUR)

[The Rainmaker]

Acura entered into a licensing and collaboration agreement with Egalet US, Inc. and Egalet Ltd. which grants Egalet worldwide rights to commercialize OXAYDO™. Currently, Acura and Egalet will be working jointly to transition the product so that it can be launched in the U.S. as soon as commercially practical.

OXAYDO™, which utilizes Acura’s AVERSION® Technology, will be sold in bottles of 100 tablets in 5mg and 7.5mg strengths. The FDA is requiring a post approval epidemiological study to assess whether OXAYDO™ results in a decrease of the consequences of misuse and abuse.
Development Program

The NDA for OXAYDO™ Tablets included results from numerous clinical and laboratory studies assessing the efficacy and safety of OXAYDO™ Tablets and to demonstrate the intended abuse deterrent features and benefits.
http://acurapharm.com/oxecta/
WAYNE, Pa., June 23, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced the deployment of its specialty sales force to support the promotion of SPRIX® (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.
http://ih.advfn.com/p.php?pid=nmona&article=67410055